Arcturus Therapeutics shares are trading lower. The company announced that it presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032 at the 47th European Cystic Fibrosis Conference.
$ARCT
Biotechnology: Pharmaceutical Preparations
Health Care
Arcturus Therapeutics shares are trading lower. The company announced that it presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032 at the 47th European Cystic Fibrosis Conference.